AI-Driven mRNA Cancer Vaccines: Precision Antigen Design & CD4⁺T-Cell Mediated Adaptive Immunity for Solid Tumors
2:30 pm - Wednesday 11th November 2026
- Engineering AI-driven mRNA cancer vaccines using the Th-Vac® platform to enable precision antigen selection and potent MHC class II–restricted CD4⁺T-cell activation in solid tumors
- Integrating a multi-epitope design strategy that coordinates CD4⁺ T helper and CD8⁺ cytotoxic T-cell responses, establishing a “helper-killer axis” for amplified and sustained anti-tumor immunity
- Advancing a differentiated immunotherapy paradigm that overcomes the resistance limitations of conventionally targeted therapies by inducing durable, adaptive immune responses against clinically relevant tumor antigens
